Decitabine
Showing 26 - 50 of 493
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Decitabine and
Recruiting
- Acute Myeloid Leukemia
- +2 more
- Decitabine and Cedazuridine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 29, 2022
Head Neck Cancer Trial in Boston (Oral Decitabine, Durvalumab)
Active, not recruiting
- Head and Neck Cancer
- Oral Decitabine
- Durvalumab
-
Boston, MassachusettsMassachusetts General Hospital
Oct 30, 2022
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Trial in Houston (Decitabine and Cedazuridine, Venetoclax)
Recruiting
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Decitabine and Cedazuridine
- Venetoclax
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Acute Myeloid Leukemia Trial in Nashville (Biopsy of Bone, Cytarabine, Daunorubicin)
Recruiting
- Acute Myeloid Leukemia
- Biospecimen Collection
- +5 more
-
Buffalo, New York
- +1 more
Jan 27, 2023
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine, Navitoclax, Venetoclax)
Recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Decitabine
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 15, 2022
Recurrent Leukemia, Refractory Leukemia Trial in Houston (Decitabine, Tegavivint)
Recruiting
- Recurrent Leukemia
- Refractory Leukemia
- Decitabine
- Tegavivint
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Acute Myeloid Leukemia, MDS, Myeloid Malignancies Trial in Boston (Decitabine, Filgrastim)
Not yet recruiting
- Acute Myeloid Leukemia
- +6 more
- Decitabine
- Filgrastim
-
Boston, Massachusetts
- +1 more
Mar 31, 2023
MDS, MDS/MPN Crossover Syndromes Trial in Cleveland (5-azacytidine, Decitabine)
Recruiting
- Myelodysplastic Syndromes
- MDS/MPN Crossover Syndromes
- 5-azacytidine
- Decitabine
-
Cleveland, OhioCleveland Medical Center, University Hospitals Seidman Cancer Ce
Aug 10, 2022
Blasts More Than 20 Percent of Bone Marrow Nucleated Cells, Blasts More Than 20 Percent of Peripheral Blood White Cells,
Completed
- Blasts More Than 20 Percent of Bone Marrow Nucleated Cells
- +4 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Acute Myelogenous Leukemia Trial in Rochester (Decitabine)
Completed
- Acute Myelogenous Leukemia
- Decitabine
-
Rochester, New YorkUniversity of Rochester
Jul 1, 2022
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +6 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 31, 2022
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +4 more
- Decitabine
- +3 more
-
Utrecht, NetherlandsPrincess Máxima Center for Pediatric Oncology
Feb 22, 2023
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (STAT
Active, not recruiting
- Acute Myeloid Leukemia
- +2 more
- STAT Inhibitor OPB-111077
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Dec 20, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Portland (Decitabine and
Not yet recruiting
- Acute Myeloid Leukemia
- +2 more
- Decitabine and Cedazuridine
- +2 more
-
Portland, OregonOHSU Knight Cancer Institute
May 25, 2022
Acute Myeloid Leukemia, Myeloid and Monocytic Leukemia, MDS Trial in Minneapolis, Saint Louis, Rochester (Decitabine,
Completed
- Acute Myeloid Leukemia
- +2 more
- Decitabine
- +2 more
-
Minneapolis, Minnesota
- +2 more
Nov 2, 2022
HIV-1-infection, Subtype b Trial (Decitabine cycle 1, Romidepsin cycle 1, Decitabine cycle 2)
Recruiting
- HIV-1-infection, Subtype b
- Decitabine cycle 1
- +7 more
-
Bruxelles, Belgium
- +2 more
Jan 30, 2023
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts Trial (Biospecimen
Not yet recruiting
- Chronic Myelomonocytic Leukemia
- +3 more
- Biospecimen Collection
- +3 more
- (no location specified)
Oct 27, 2022
Acute Myeloid Leukemia Trial in Baltimore (Decitabine, talazoparib)
Active, not recruiting
- Acute Myeloid Leukemia
- Decitabine
- talazoparib
-
Baltimore, MarylandUniversity of Maryland Greenebaum Comprehensive Cancer Center
May 31, 2022
Vulvar Intraepithelial Neoplasia Grade 2, Vulvar Intraepithelial Neoplasia Grade 3 Trial (VTD-101 ointment)
Not yet recruiting
- Vulvar Intraepithelial Neoplasia Grade 2
- Vulvar Intraepithelial Neoplasia Grade 3
- VTD-101 ointment
- (no location specified)
Feb 3, 2023
Leukemia Trial in Houston (Cladribine, Cytarabine, Decitabine)
Recruiting
- Leukemia
- Cladribine
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Aug 23, 2022
Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,
Recruiting
- Acute Myeloid Leukemia
- +8 more
- Decitabine
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 18, 2022
Breast Tumor Trial in Shanghai (Decitabine, Carboplatin)
Terminated
- Breast Neoplasm
- Decitabine
- Carboplatin
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiaotong University School of Medicine
Mar 28, 2022
Acute Myeloid Leukemia Trial in Nanjing (Venetoclax-Decitabine/Azacitidine-Aclarubicin Association,
Recruiting
- Acute Myeloid Leukemia
- Venetoclax-Decitabine/Azacitidine-Aclarubicin Association
- Venetoclax-Decitabine/Azacitidine Association
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Mar 2, 2022